Q2 Earnings Forecast for Entera Bio Issued By HC Wainwright

Entera Bio Ltd. (NASDAQ:ENTX) – HC Wainwright increased their Q2 2026 EPS estimates for Entera Bio in a research note issued to investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.08) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Entera Bio’s current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Entera Bio’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.34) EPS.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Entera Bio currently has an average rating of “Hold” and an average target price of $9.00.

Entera Bio Stock Up 6.8%

Shares of ENTX stock opened at $1.25 on Wednesday. The company has a market cap of $61.53 million, a P/E ratio of -4.63 and a beta of 1.54. The business has a 50 day moving average of $1.22 and a two-hundred day moving average of $1.71. Entera Bio has a 52 week low of $0.91 and a 52 week high of $3.22.

Institutional Investors Weigh In On Entera Bio

Several hedge funds have recently modified their holdings of the stock. Superstring Capital Management LP purchased a new position in Entera Bio in the 4th quarter worth about $33,000. Citadel Advisors LLC grew its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares in the last quarter. HighTower Advisors LLC increased its position in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the last quarter. Jane Street Group LLC raised its position in shares of Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after purchasing an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after buying an additional 19,601 shares during the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Geno J. Germano acquired 20,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were bought at an average price of $1.30 per share, with a total value of $26,000.00. Following the purchase, the director owned 40,000 shares of the company’s stock, valued at approximately $52,000. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.38% of the company’s stock.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.